Clover Biopharmaceuticals, Ltd. (2197.HK)
HKD 0.31
(-4.62%)
HKD 0.31
(-4.62%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 24.24 Million CNY | -51.84% |
| 2022 | 1.86 Billion CNY | -13.75% |
| 2021 | 2.15 Billion CNY | 659.01% |
| 2020 | 284.28 Million CNY | 505.84% |
| 2019 | 46.92 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 73.52 Million CNY | -61.89% |
| 2024 Q2 | 73.52 Million CNY | 0.0% |
| 2023 FY | 896.33 Million CNY | -51.84% |
| 2023 Q2 | 944.6 Million CNY | 0.0% |
| 2023 Q1 | 944.6 Million CNY | 126.84% |
| 2023 Q4 | 192.94 Million CNY | 9.63% |
| 2023 Q3 | 175.98 Million CNY | -81.37% |
| 2022 Q2 | 573 Million CNY | 0.0% |
| 2022 Q1 | 573 Million CNY | -75.31% |
| 2022 FY | 1.86 Billion CNY | -13.75% |
| 2022 Q4 | 416.41 Million CNY | 0.0% |
| 2022 Q3 | 416.41 Million CNY | -27.33% |
| 2021 Q2 | 655.48 Million CNY | 0.0% |
| 2021 FY | 2.15 Billion CNY | 659.01% |
| 2021 Q4 | 2.32 Billion CNY | 0.0% |
| 2021 Q3 | 2.32 Billion CNY | 254.07% |
| 2021 Q1 | 655.48 Million CNY | 0.0% |
| 2020 FY | 284.28 Million CNY | 505.84% |
| 2019 FY | 46.92 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 325.05 Million HKD | 92.542% |
| CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | 96.721% |